EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Progress in Glioma Stem Cell Research

Vanajothi Ramar, Shanchun Guo iD, BreAnna Hudson, Mingli Liu

Cancers · 24.12.2023 · 16 (1) · 102

DOI: 10.3390/cancers16010102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.12.2023. Verfasst von Vanajothi Ramar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIH/NIGMS SC1 GM144021 (ML).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) represents a diverse spectrum of primary tumors notorious for their resistance to established therapeutic modalities. Despite aggressive interventions like surgery, radiation, and chemotherapy, these tumors, due to factors such as the blood–brain barrier, tumor heterogeneity, glioma stem cells (GSCs), drug efflux pumps, and DNA damage repair mechanisms, persist beyond complete isolation, resulting in dismal outcomes for glioma patients. Presently, the standard initial approach comprises surgical excision followed by concurrent chemotherapy, where temozolomide (TMZ) serves as the foremost option in managing GBM patients. Subsequent adjuvant chemotherapy follows this regimen. Emerging therapeutic approaches encompass immunotherapy, including checkpoint inhibitors, and targeted treatments, such as bevacizumab, aiming to exploit vulnerabilities within GBM cells. Nevertheless, there exists a pressing imperative to devise innovative strategies for both diagnosing and treating GBM. This review emphasizes the current knowledge of GSC biology, molecular mechanisms, and associations with various signals and/or pathways, such as the epidermal growth factor receptor, PI3K/AKT/mTOR, HGFR/c-MET, NF-κB, Wnt, Notch, and STAT3 pathways. Metabolic reprogramming in GSCs has also been reported with the prominent activation of the glycolytic pathway, comprising aldehyde dehydrogenase family genes. We also discuss potential therapeutic approaches to GSC targets and currently used inhibitors, as well as their mode of action on GSC targets.

Schlagwörter

Stichwörter der Autor:innen

GSCsNF-κBTMZdrug targetsglioblastomamolecular mechanism

Autor:innen und Institutionen

  • Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • Department of Chemistry, Xavier University, 1 Drexel Dr., New Orleans, LA 70125, USA.

ORCID-Profile: Shanchun Guo

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NIH/NIGMS SC1 GM144021 (ML)
  • NIH NIGMS U54GM104940

Zitieren

APA

Ramar, V., Guo, S., Hudson, B., & Liu, M. (2023). Progress in Glioma Stem Cell Research. Cancers, 16(1), 102. https://doi.org/10.3390/cancers16010102

Vancouver

Ramar V, Guo S, Hudson B, Liu M. Progress in Glioma Stem Cell Research. Cancers. 2023;16(1):102. doi:10.3390/cancers16010102

BibTeX
@article{Ramar2023,
  author = {Ramar, Vanajothi and Guo, Shanchun and Hudson, BreAnna and Liu, Mingli},
  title = {Progress in Glioma Stem Cell Research},
  journal = {Cancers},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {102},
  doi = {10.3390/cancers16010102}
}
Kostenlos starten →